The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter.
SI-BONE Inc
SIBN · NASDAQ · USD · Market cap $771M · 376 employees
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price23.44 USD at the 13 Nov 2026 close
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.01)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $18.00 to $32.00, base estimate $24.00 (screen dated 2026-11-13).
- Trend Markup
- Insiders insiders sold, $1,897,643, latest filing 2026-11-04
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.01, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
SI-BONE Inc holds its Markup at $23.44. The statistical read favours the sellers, held for 3 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 3 days |
| Price at the screen | $23.44 |
| Valuation | N/A trailing · -49.25 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.67 |
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 15.38% | Below 33% | Interest-bearing debt is just 15.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 44.26% | Below 33% | Interest-bearing cash and securities are 44.3% of assets, above the one-third limit. | Fail |
| Receivables | 30.25% | Below 49% | Money owed to the company is 30.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 3.02% | Below 5% | Only 3.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
SI-BONE's business is fine, but its cash and interest-bearing securities are about 44% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SIBN's ethical verdict changes
Today SIBN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades at roughly a 2% discount to our $24.00 fair value, none competitive moat, 11.20% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 2.3% discount to the base estimate.
Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +2% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & ProjectionsWhere our models see it going: fair-value estimate $24.00, with a range of $18.00 to $32.00, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a none moat. It trades close to our $24.00 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | -49.3x |
| EPS, trailing | -0.39 |
| EPS, forward | -0.35 |
| Revenue growth | +11.2%steady growth |
| Profit margin | -8.1%currently unprofitable |
| Return on equity | -9.6%not currently earning a positive return on equity |
| FCF yield | -0.34% |
| Debt to equity | 0.24minimal debt: a conservative balance sheet |
| Current ratio | 9.99comfortably covers its short-term bills |
| Beta | 0.67steadier than the market |
| Short interest, float | 0.16% |
| 52-week range | 11.48 - 21.89 |
| Moat | NONE |
| Market cap | $771M |
| Employees | 376 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSIBN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. Since the last review it entered the Titan Ethical 500; dropped out of the Titan Ethical 500; its composite score eased.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Pisetsky Michael A. | SVP, Ops, Adm, Chief Legal Ofr | S - Sale+OE | 36,241 | $901,844 |
| 2026-11-04 | Francis Laura | CEO | S - Sale | 75,000 | $1,897,643 |
| 2026-11-04 | Pisetsky Michael A. | SVP, Ops, Adm, Chief Legal Ofr | S - Sale | 36,241 | $898,802 |
| 2026-11-04 | Maheshwari Anshul | Chief Op, Financial Officer | S - Sale | 3,247 | $81,175 |
| 2026-11-02 | Dunn Jeffrey W | Dir | S - Sale+OE | 20,000 | $417,820 |
| 2026-10-29 | Pisetsky Michael A. | SVP, Ops, Adm, Chief Legal Ofr | S - Sale | 29,665 | $655,745 |
| 2026-10-29 | Maheshwari Anshul | Chief Op, Financial Officer | S - Sale | 3,738 | $84,105 |
| 2026-10-12 | Francis Laura | CEO | S - Sale | 38,006 | $762,013 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $11.61 | +32.4% | · | $1,324 | +32.4% |
| 2 months | $12.84 | +19.7% | · | $1,197 | +19.7% |
| 3 months | $13.82 | +11.2% | · | $1,112 | +11.2% |
| 6 months | $18.82 | -18.3% | · | $817 | -18.3% |
| 1 year | $19.10 | -19.5% | · | $805 | -19.5% |
| 2 years | $13.15 | +16.9% | · | $1,169 | +16.9% |
| 3 years | $28.01 | -45.1% | · | $549 | -45.1% |
| 5 years | $31.39 | -51.0% | · | $490 | -51.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SIBN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.